SLC8B1: A Potential Drug Target for Neurodegenerative Diseases

Target Name: SLC8B1

NCBI ID: G80024

SLC8B1

SLC8B1: A Potential Drug Target for Neurodegenerative Diseases

SLC8B1 (SLC8B1 variant 1) is a protein that is expressed in various tissues of the body, including the brain, heart, and pancreas. It is a member of the solute carrier family 8 (SLC8) and contains 184 amino acid residues. SLC8B1 is also known as SLC8B1-V1 because one of its splice variants is V1.

SLC8B1 is involved in a variety of physiological processes in the body, including cell signaling, neurotransmitter transport, and insulin sensitivity. It is also expressed in various diseases, including Alzheimer's disease, Parkinson's disease, and type 2 diabetes. Therefore, SLC8B1 is a potential drug target or biomarker for these diseases.

SLC8B1 has been shown to play a role in neurotransmitter transport in the brain. It is involved in the transport of various neurotransmitters, including dopamine, serotonin, and endocannabinoids. SLC8B1 has been shown to regulate the levels of these neurotransmitters in the brain and to play a role in their signaling.

SLC8B1 has also been shown to be involved in cell signaling. It is a member of the T-cell receptor tyrosine kinase (TCR) signaling pathway, which is involved in the regulation of immune responses and cell signaling. SLC8B1 has been shown to be involved in the regulation of TCR signaling by regulating the activity of the protein tyrosine kinase (TK).

SLC8B1 has also been shown to be involved in insulin sensitivity. It is expressed in tissues that are important for insulin sensitivity, including the skeletal muscles and the pancreas. SLC8B1 has been shown to play a role in the regulation of insulin sensitivity by regulating the activity of the protein p110GTP.

In addition to its involvement in neurotransmitter transport, SLC8B1 has also been shown to be involved in the regulation of inflammation. It is a member of the integrins family and has been shown to participate in the regulation of inflammation and immune responses.

SLC8B1 has also been shown to be involved in the regulation of cell adhesion. It is a member of the cadherin family and has been shown to play a role in the regulation of cell adhesion.

SLC8B1 has also been shown to be involved in the regulation of cell survival. It is a member of the B-cell maturation antigen (BCMA) family and has been shown to play a role in the regulation of cell survival.

In conclusion, SLC8B1 is a protein that is involved in a variety of physiological processes in the body. It is a potential drug target or biomarker for diseases such as Alzheimer's disease, Parkinson's disease, and type 2 diabetes due to its involvement in neurotransmitter transport, cell signaling, insulin sensitivity, and inflammation. Further research is needed to fully understand the role of SLC8B1 in these diseases.

Protein Name: Solute Carrier Family 8 Member B1

Functions: Mitochondrial sodium/calcium antiporter that mediates sodium-dependent calcium efflux from mitochondrion, by mediating the exchange of 3 sodium ions per 1 calcium ion (PubMed:20018762, PubMed:22829870, PubMed:23056385, PubMed:24898248, PubMed:28219928). Plays a central role in mitochondrial calcium homeostasis by mediating mitochondrial calcium extrusion: calcium efflux is essential for mitochondrial function and cell survival, notably in cardiomyocytes (By similarity). Regulates rates of glucose-dependent insulin secretion in pancreatic beta-cells during the first phase of insulin secretion: acts by mediating efflux of calcium from mitochondrion, thereby affecting cytoplasmic calcium responses (PubMed:23056385). Required for store-operated Ca(2+) entry (SOCE) and Ca(2+) release-activated Ca(2+) (CRAC) channel regulation: sodium transport by SLC8B1 leads to promote calcium-shuttling that modulates mitochondrial redox status, thereby regulating SOCE activity (PubMed:28219928). Involved in B-lymphocyte chemotaxis (By similarity). Able to transport Ca(2+) in exchange of either Li(+) or Na(+), explaining how Li(+) catalyzes Ca(2+) exchange (PubMed:15060069). In contrast to other members of the family its function is independent of K(+) (PubMed:15060069)

The "SLC8B1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SLC8B1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets